View the conference agenda for WCMC, a dedicated forum for oncologists involved in the management of patients with cutaneous malignancies. 

*Agenda subject to change.

Friday | September 30th, 2016

7:00-8:30 AM

Breakfast/Product Theater (non-CME/CE)

8:30-8:45 AM

Break (non-CME/CE)

8:45-9:00 AM

Welcome and Program Overview – Sanjiv Agarwala, MD 

9:00-9:30 AM

An Overview of Cutaneous Malignancies: Outlining the Clinical Features of Melanoma and Nonmelanoma Skin Cancers – Scott Fosko, MD 

9:30-10:30 AM

Melanoma Post-ASCO® Update: What’s New and Exciting

  • Immunotherapy – Michael Atkins, MD
  • Targeted therapy – Michael Atkins, MD

10:30-10:45 AM

Break (non-CME/CE)

10:45-11:15 AM

Keynote Lecture: Making Sense of New Molecular Targets in Melanoma – Meenhard Herlyn, DVM, DSc

11:15 AM-12:15 PM

A Dermatologist’s Perspective on Cutaneous Malignancies

  • Screening for melanoma and other cutaneous Malignancies – Axel Hauschild, MD
  • Diagnosis of melanoma—advances in new technologies -Ashfaq Marghoob, MD 

12:15-1:15 PM

Lunch/Product Theater (non-CME/CE)

1:15-1:30 PM

Break (non-CME/CE)

1:30-2:30 PM

Surgical and Locoregional Therapy in Melanoma

  • Role of completion lymphadenectomy – Vernon Sondak, MD
  • Intralesional therapy – Robert Andtbacka, MD, CM
  • The changing role of surgery in the era of targeted therapy – Merrick Ross, MD
  • Panel Discussion

2:30-2:45 PM

Molecular Biomarkers in Cutaneous Malignancies: Are We There Yet? – Ryan J. Sullivan, MD 

2:45-3:45 PM

Making Sense of New Molecular Targets in Nonmelanoma Skin Cancers: Implications for Clinical Practice 

  • BCC: Jean Tang, MD, PhD
  • CTCL: Madeleine Duvic, MD (“Targeted Antibodies in CTCL”)
  • MCC: Shailender Bhatia, MD

3:45-4:30 PM

Emerging Concepts in BCC

  • Therapeutic resistance – Dirk Schadendorf, MD
  • New approaches to therapy – Alex Sekulic, MD, PhD

4:30-6:30 PM

Cocktail Reception/Networking (non-CME/CE)

Saturday | October 1st, 2016

7:00-8:00 AM

Breakfast/Product Theater (non-CME/CE)

8:00-8:15 AM

Break (non-CME/CE)

8:15-8:45 AM

Therapeutic Advances in CTCL in the Era of Molecular Targeting – Youn Kim, MD

8:45-9:30 AM

Metastatic Melanoma: Current Status of MAPK-Targeted Therapies – Jeff Sosman, MD

9:30-10:15 AM

Metastatic Melanoma: Current Status of Immune Checkpoint Inhibitors – Michael Postow, MD

10:15-10:30 AM

Break (non-CME/CE)

10:30–11:30 AM

Sequencing Therapies in Metastatic Melanoma

  • Making sense of treatment algorithms – Jason Luke, MD
  • Combining immunotherapy and targeted therapy in BRAF-mutated melanoma–are we there yet? – Michael Davies, MD, PhD

11:30 AM- 12:00 Noon

Emerging Targets in Melanoma: A Look to the Future

  • Emerging immune checkpoint inhibitors – Igor Puzanov, MD, MSCI, FACP
  • Other molecular/gene mutation targets – Dirk Schadendorf, MD 

12:00-1:00 PM

Lunch/Product Theater (non-CME/CE)

1:00-1:15 PM

Break (non-CME/CE)

1:15-2:00 PM

Emerging Therapies for MCC – Paul Nghiem, MD, PhD

2:00 PM

Closing Remarks – Sanjiv Agarwala, MD